L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: Pooled PORTEC trial results

European Journal of Cancer

Volumn 50, Issue 15, 2014, Pages 2602-2610

  Bosse, T ^a   Nout, R A ^a   Stelloo, E ^a   Dreef, E ^a   Nijman, H W ^b   Jurgenliemk Schulz I M ^c   Jobsen, J J ^d   Creutzberg, C L ^a   Smit, V T H B M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d MEDISCH SPECTRUM TWENTE   (Netherlands)

Author keywords

Endometrial cancer; L1CAM; PORTEC; Prognostic marker

Indexed keywords

NERVE CELL ADHESION MOLECULE L1;

ADULT; AGED; CANCER STAGING; ENDOMETRIAL NEOPLASMS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEURAL CELL ADHESION MOLECULE L1; POSTOPERATIVE PERIOD; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 84907430202     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.07.014     Document Type: Article

References (35)

1. W.T. Creasman, F. Odicino, and P. Maisonneuve Carcinoma of the corpus uteri. FIGO 26th annual report on the results of treatment in gynecological cancer Int J Gynaecol Obstet 95 Suppl. 1 2006 S105 S143
2. A. Kong, N. Johnson, H.C. Kitchener, and T.A. Lawrie Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis J Natl Cancer Inst 104 21 2012 1625 1634
3. A.G. Zeimet, D. Reimer, and M. Huszar L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation J Natl Cancer Inst 105 15 2013 1142 1150
4. M. Fogel, P. Gutwein, and S. Mechtersheimer L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas Lancet 362 9387 2003 869 875
5. M. Huszar, M. Pfeifer, and U. Schirmer Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas J Pathol 220 5 2010 551 561
6. M. Fogel, S. Mechtersheimer, and M. Huszar L1 adhesion molecule (CD 171) in development and progression of human malignant melanoma Cancer Lett 189 2 2003 237 247
7. N. Gavert, M. Conacci-Sorrell, and D. Gast L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers J Cell Biol 168 4 2005 633 642
8. H. Kiefel, S. Bondong, and N. Erbe-Hoffmann L1CAM-integrin interaction induces constitutive NF-kappaB activation in pancreatic adenocarcinoma cells by enhancing IL-1beta expression Oncogene 29 34 2010 4766 4778
9. C. Schroder, U. Schumacher, and M. Fogel Expression and prognostic value of L1-CAM in breast cancer Oncol Rep 22 5 2009 1109 1117
10. V. Tischler, M. Pfeifer, and S. Hausladen L1CAM protein expression is associated with poor prognosis in non-small cell lung cancer Mol Cancer 10 2011 127
11. H. Kiefel, S. Bondong, and J. Hazin L1CAM: a major driver for tumor cell invasion and motility Cell Adh Migr 6 4 2012 374 384
12. S. Silletti, M. Yebra, B. Perez, V. Cirulli, M. McMahon, and A.M. Montgomery Extracellular signal-regulated kinase (ERK)-dependent gene expression contributes to L1 cell adhesion molecule-dependent motility and invasion J Biol Chem 279 28 2004 28880 28888
13. F. Meier, S. Busch, and D. Gast The adhesion molecule L1 (CD171) promotes melanoma progression Int J Cancer 119 3 2006 549 555
14. S. Tsutsumi, S. Morohashi, and Y. Kudo L1 cell adhesion molecule (L1CAM) expression at the cancer invasive front is a novel prognostic marker of pancreatic ductal adenocarcinoma J Surg Oncol 103 7 2011 669 673
15. Y. Kajiwara, H. Ueno, and Y. Hashiguchi Expression of l1 cell adhesion molecule and morphologic features at the invasive front of colorectal cancer Am J Clin Pathol 136 1 2011 138 144
16. Y.Y. Wang, L. Li, Z.S. Zhao, Y.X. Wang, Z.Y. Ye, and H.Q. Tao L1 and epithelial cell adhesion molecules associated with gastric cancer progression and prognosis in examination of specimens from 601 patients J Exp Clin Cancer Res 32 1 2013 66
17. Y. Kodera, H. Nakanishi, and S. Ito Expression of L1 cell adhesion molecule is a significant prognostic factor in pT3-stage gastric cancer Anticancer Res 29 10 2009 4033 4039
18. Y. Allory, Y. Matsuoka, C. Bazille, E.I. Christensen, P. Ronco, and H. Debiec The L1 cell adhesion molecule is induced in renal cancer cells and correlates with metastasis in clear cell carcinomas Clin Cancer Res 11 3 2005 1190 1197
19. U.H. Weidle, D. Eggle, and S. Klostermann L1-CAM as a target for treatment of cancer with monoclonal antibodies Anticancer Res 29 12 2009 4919 4931
20. C.L. Creutzberg, W.L. van Putten, and P.C. Koper Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC study group. Post operative radiation therapy in endometrial carcinoma Lancet 355 9213 2000 1404 1411
21. R.A. Nout, L.V. van de Poll-Franse, and M.L. Lybeert Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial J Clin Oncol 29 13 2011 1692 1700
22. R.A. Nout, V.T. Smit, and H. Putter Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial Lancet 375 9717 2010 816 823
23. T. Bosse, N.T. Ter Haar, and L.M. Seeber Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer Mod Pathol 26 11 2013 1525 1535
24. M. Fogel, A. Harari, E. Muller-Holzner, A.G. Zeimet, G. Moldenhauer, and P. Altevogt A standardized staining protocol for L1CAM on formalin-fixed, paraffin-embedded tissues using automated platforms Int J Biol Markers 29 2 2014 e180 e183
25. S.S. Muerkoster, J. Lust, and A. Arlt Acquired chemoresistance in pancreatic carcinoma cells: induced secretion of IL-1beta and NO lead to inactivation of caspases Oncogene 25 28 2006 3973 3981
26. S. Wolterink, G. Moldenhauer, and M. Fogel Therapeutic antibodies to human L1CAM: functional characterization and application in a mouse model for ovarian carcinoma Cancer Res 70 6 2010 2504 2515
27. H. Schafer, C. Dieckmann, and O. Korniienko Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma Cancer Lett 319 1 2012 66 82
28. M.J. Arlt, I. Novak-Hofer, and D. Gast Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment Cancer Res 66 2 2006 936 943
29. U. Schirmer, K. Doberstein, and A.K. Rupp Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma Oncotarget 5 2 2014 462 472
30. T. Tsuzuki, S. Izumoto, T. Ohnishi, S. Hiraga, N. Arita, and T. Hayakawa Neural cell adhesion molecule L1 in gliomas: correlation with TGF-beta and p53 J Clin Pathol 51 1 1998 13 17
31. E. Colas, N. Pedrola, and L. Devis The EMT signaling pathways in endometrial carcinoma Clin Transl Oncol 14 10 2012 715 720
32. N. Gavert, A. Ben-Shmuel, S. Raveh, and A. Ben-Ze'ev L1-CAM in cancerous tissues Expert Opin Biol Ther 8 11 2008 1749 1757
33. N. Gavert, M. Sheffer, and S. Raveh Expression of L1-CAM and ADAM10 in human colon cancer cells induces metastasis Cancer Res 67 16 2007 7703 7712
34. H. Kiefel, S. Bondong, and M. Pfeifer EMT-associated up-regulation of L1CAM provides insights into L1CAM-mediated integrin signalling and NF-kappaB activation Carcinogenesis 33 10 2012 1919 1929
35. C. Geismann, A. Arlt, and I. Bauer Binding of the transcription factor Slug to the L1CAM promoter is essential for transforming growth factor-beta1 (TGF-beta)-induced L1CAM expression in human pancreatic ductal adenocarcinoma cells Int J Oncol 38 1 2011 257 266